Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 58,400 shares, an increase of 349.2% from the September 15th total of 13,000 shares. Based on an average trading volume of 6,400,000 shares, the days-to-cover ratio is presently 0.0 days.

Aptevo Therapeutics Price Performance

Shares of APVO stock opened at $0.15 on Friday. Aptevo Therapeutics has a one year low of $0.14 and a one year high of $21.56. The company has a 50 day moving average price of $0.30 and a 200 day moving average price of $0.82.

Aptevo Therapeutics (NASDAQ:APVO) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, topping the consensus estimate of ($1.93) by $0.26. Equities analysts predict that Aptevo Therapeutics will post -4.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. StockNews.com began coverage on Aptevo Therapeutics in a research report on Sunday, October 6th. They issued a “sell” rating for the company. Roth Mkm decreased their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, September 23rd.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is currently owned by institutional investors and hedge funds.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.